PREVNAR 13 Rx
Generic Name and Formulations:
Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) 30.8micrograms of saccharides per 0.5mL; susp for IM inj; contains aluminum.
Indications for PREVNAR 13:
Immunization of children age 6 weeks to 5 years of age (before 6th birthday) against invasive disease caused by S. pneumoniae due to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and against otitis media due to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Immunization of children 6–17 years of age (before 18th birthday) against invasive disease caused by S. pneumoniae due to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Immunization of adults ≥50 years of age against pneumonia and invasive disease caused by S. pneumoniae due to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
Adults and Children:
Each dose is 0.5mL IM into the anterolateral thigh for infants or the deltoid muscle for toddlers, children and adults; avoid nerves and blood vessels. May pretreat with antipyretic. <6 weeks: not established. ≥6 weeks: 4 doses usually given at 2, 4, 6, and 12–15 months of age (may start at 6 weeks of age: give first 3 doses 4–8 weeks apart, and 4th dose at least 2 months after 3rd dose). Previously unvaccinated older infants and children: 7–11 months of age: 3 doses (2nd dose at least 4 weeks after 1st dose, 3rd dose after 1st birthday and at least 2 months after 2nd dose); 12–23 months of age: 2 doses at least 2 months apart; 2–5 years of age: 1 dose once. Previously vaccinated with Prevnar: may complete 4-dose series with Prevnar 13; if series is completed and 15 months–5 years of age: may receive 1 dose of Prevnar 13, given at least 8 weeks after final dose of Prevnar. 6–17 years of age: a single dose; if previously vaccinated with Prevnar, then at least 8 weeks should elapse before receiving Prevnar 13. ≥50 years: a single dose.
Allergies to any diphtheria toxoid-containing vaccine.
Not for protection against disease caused by S. pneumoniae serotypes that are not in the vaccine. Immunocompromised. Have epinephrine inj available. Premature infants. Pregnancy (Cat.B). Nursing mothers.
Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response. Antibody responses may be diminished with concomitant inactivated influenza virus vaccine.
Inj site reactions, fever, decreased appetite, irritability, increased or decreased sleep, drowsiness, diarrhea, vomiting, rash, hives, fatigue, headache, chills, muscle and joint pain.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds